You are here:

Emtricitabine/tenofovir disoproxil 200 mg / 245 mg tablet (Truvada®)


Following an abbreviated submission

Emtricitabine/tenofovir disoproxil 200 mg/245 mg tablet (Truvada) is accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults in combination with other antiretroviral medicinal products. Both constituents are nucleoside reverse transcriptase inhibitors. The demonstration of the benefit of the combination emtricitabine and tenofovir disoproxil fumarate in antiretroviral therapy is based solely on studies performed in treatment-naïve patients.

Drug Details

Drug Name: Emtricitabine/tenofovir disoproxil 200 mg / 245 mg tablet (Truvada®)
SMC Drug ID: 237/06
Manufacturer: Gilead Sciences Ltd
Indication: HIV
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 February 2006